Rigel Pharmaceuticals Inc — Liquidità Trimestrale (NASDAQ:RIGL) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 163.98 M175.97 M206.74 M242.53 M513.59 M Totale passività 160.69 M157.41 M124.8 M124.92 M122.11 M Patrimonio netto totale 3.29 M18.57 M81.93 M117.61 M391.48 M Totale passività e patrimonio netto 163.98 M175.97 M206.74 M242.53 M513.59 M Debito totale 59.68 M59.75 M59.81 M59.73 M52.29 M Indebitamento netto -17.64 M-17.41 M-48.62 M-77.47 M-102.72 M

Notizie

Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (NASDAQ:RIGL)

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Micron and Coinbase among market cap stock movers on Wednesday

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript

Rigel Q4 2025: crescita annuale del 60%, dati promettenti su MDS

Rigel Q4 2025 slides: 60% annual growth, promising MDS data

Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan

Implied Volatility Surging for Rigel Pharmaceuticals Stock Options

Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates